Leflunomide is a drug used in rheumatoid arthritis with teratogenic and fetotoxic effects. Clinical data on human pregnancies are limited to a few case reports without detailed information whether the mothers did have a washout procedure as suggested by the manufacturer or what type of malformation the offspring showed. We report on a set of twins born after maternal exposure to leflunomide who had a largely normal neonatal outcome, providing information about the washout procedure and the blood level of the active metabolite. (2008) Background Arava (leflunomide) is a new drug for the treatment of rheumatoid arthritis. This pyrimidine synthesis inhibitor has teratogenic and fetotoxic effects, inducing skeletal and central nervous system malformations in rats and rabbits.
Background Arava (leflunomide) is a new drug for the treatment of rheumatoid arthritis. This pyrimidine synthesis inhibitor has teratogenic and fetotoxic effects, inducing skeletal and central nervous system malformations in rats and rabbits. 1, 2 Clinical data on humans are limited. [2] [3] [4] For that reason leflunomide is contraindicated during pregnancy; women of childbearing age must use reliable contraception. On account of to the long half-life of the active metabolite A77 1726, leflunomide should be withdrawn 2 years before planning a pregnancy. Alternatively, an 11-day washout procedure with oral cholestyramine may be performed, which leads to a rapid and significant decline in blood level according to the manufacturer. This aims to achieve a blood level of the active metabolite that is less than 0.02 mg l À1 , which according to the manufacturer is regarded safe. The scientific basis for this critical value is that it is more than 100 times lower than the blood level in rats and rabbits which has been determined as the no-effect level regarding embryotoxicity and teratogenicity. 1 Existing case reports do not provide information whether the women reported on had undergone a washout procedure, or on the blood levels of the active metabolite or the type of malformation found in the offspring. We report such information for a set of twins.
Case report
A 35-year-old woman suffered from juvenile polyarthritis from age 3. She was treated with methotrexate for several years, which was replaced by leflunomide due to secondary treatment failure. Because of her desire to become pregnant the drug was withdrawn, but no washout procedure was performed. Twelve weeks later she conceived. When the pregnancy was diagnosed, a cholestyramine washout procedure was conducted. The blood level for A7 1726 before washout was <0.2 mg l À1 , thereafter it had increased to 0.5 mg l À1 . This increase remained unexplained. According to the mother, there was no co-medication that could have led to this increase and no change in clinical symptoms occurred during this time. According to the laboratory, the variation limit of the test is about 15%, which would not explain the difference observed. The laboratory, however, regarded both values measured as indicative of negative blood levels for leflunomide, as it is not possible to measure blood levels in the 0.02 mg l À1 range, which is the target value after a washout procedure. A further blood level analysis was not performed. Although the measured blood levels were obviously lower then the therapeutic level of leflunomide they were higher than the level, which according to the manufacturer is regarded save.
The mother was advised to interrupt the pregnancy but decided against this advice. Pregnancy was complicated by monozygotic monochorial diamniotic twins and preeclampsia. This led to placental insufficiency of one fetus with subsequent intrauterine growth retardation and oligohydramnios. Signs of fetal distress led to delivery by Caesarean section at 29 þ 4 weeks of gestation.
Neonatal outcome
The first twin was a girl of 1400 g who had normal weight, length and head circumference for gestational age. She had no congenital malformations; head and abdominal ultrasound were unremarkable. She was treated with continuous positive airway pressure (CPAP) and developed a right-sided pneumothorax but continued to breathe spontaneously. Apnea of prematurity was treated with caffeine. A hemorrhagic enterocolitis on day 10, accompanied by prolonged apneas, paralytic ileus and clinical deterioration, necessitated endotracheal intubation, discontinuation of enteral feedings and antibiotic therapy for 7 days.
Echocardiography revealed a patent ductus arteriosus, which closed with indomethacin, an atrioseptal defect and some small muscular ventricular septal defects, which became smaller during her hospital stay. Otherwise, her neonatal course was unremarkable and she was discharged home at 36 þ 3 weeks of gestation.
The second twin was born small-for-gestational age (SGA), weighing 740 g (<3rd centile). She was treated with CPAP and caffeine for apnea of prematurity. On day 8 she developed a bacterial infection, which was treated with antibiotics for 3 days. During her first days of life oral feeding advancement was delayed due to reduced intestinal motility as often seen in SGA preterms.
Echocardiography showed an open ductus arteriosus, which was treated with indomethacin. Head and abdominal ultrasound were unremarkable. Except for a slight elongation of the caudal vertebrae combined with a sacral dimple, no congenital malformations were found. An ultrasound of that region showed a discrete dysplasia of coccygeal vertebrae without pathological findings of spinal canal or medullary conus. She was discharged home at 36 þ 3 weeks of gestation, still with all parameters under the third percentile.
Follow up
At follow up at an adjusted age of 3 months the first twin showed satisfying growth with normal weight, length and head circumference. Her sister was still below the third percentile with all parameters but showed some catch-up growth. Both the girls showed a normal neurocognitive development. On echocardiography, the ventricular septal defects in the first twin had closed and the atrioseptal defect had further minimized.
Discussion
Leflunomide is a new drug with known teratogenic potential in rats and rabbits. 2 Clinical data are limited, there are only a few case reports; a prospective multicenter cohort study is currently in progress. 5 Taken together, the cases reported in the literature total 355 women who had become pregnant shortly after discontinuation of or during leflunomide treatment. [1] [2] [3] [4] In 153 of these cases there is no information as to whether the women had interrupted their pregnancy, had a spontaneous abortion or carried out their pregnancy, nor about the neonatal outcome. Among the remaining 202 women with further information available, 75 (37%) elected to terminate the pregnancy, 37 (18%) had a spontaneous abortion, 83 (41%) gave birth to a child without malformations and 7 (3.5%) gave birth to a child with congenital malformations. Of the reported seven children with congenital malformations, no further information is given on the type of malformation found.
A problem with the existing case reports is that they do not give accurate information on the blood level of the active metabolite of leflunomide found in the women. Brent 1 reports that the women were exposed to therapeutic levels, but only three women decided to maintain their pregnancies and there is no further information about the outcome of the offspring. Only De Santis et al. 3 report that none of the women in their report performed a washout procedure.
It is always difficult for a family to be faced with a recommendation to interrupt a pregnancy. Lacking data on the kind of malformations that may occur with leflunomide, on the blood level of the active metabolite under which these malformations may occur and on whether the affected women had performed a washout procedure does not make the decision easier.
To our knowledge, this is the first case report providing such detailed information. We report on a pair of twins born after maternal exposure to leflunomide, which was stopped 12 weeks before conceiving. Unexpectedly the blood level of the active metabolite rose after the washout procedure, which had been performed as soon as the pregnancy was noticed.
The children were born preterm because of preeclampsia, which had led to intrauterine growth retardation of the second twin. The first twin had an atrioseptal defect and some small muscular ventricular septal defects. These are two of the most common congenital heart defects, with a high rate of spontaneous closure. 6 Because the ventricular septal defects closed spontaneously and the atrioseptal defect minimized, they cannot be considered major congenital anomalies in our opinion.
The second twin had a sacral dimple with discrete dysplasia of coccygeal vertebrae without further pathological findings. It is speculative if these malformations were due to leflunomide. After all, in our opinion, it was appropriate for that family to decide against interrupting the pregnancy. Nevertheless, the proven teratogenic and fetotoxic effects of leflunomide in animal studies and the lack of data on its effects in humans must lead to a very careful use of leflunomide in women of childbearing potential as recommended in the literature. Prospective studies with a higher number of cases and detailed information about the kind of malformations occurring are necessary.
